- Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South…Endpoints · 1mo ago↗ source
- #ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T updateCHICAGO — Eli Lilly in April signed an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...Endpoints · 1mo ago↗ source
- After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingAvenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...